Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etentamig in Combination With Pomalidomide in Relapsed or Refractory Multiple Myeloma
NCT07728188Phase 3Not yet recruiting
- Sponsor
- AbbVie Inc.
- Start
- Nov 2026
- Primary completion
- Feb 2033
- Countries
- 13
01
Overview
A Phase 3 trial of etentamig in multiple myeloma (MM), sponsored by AbbVie Inc.. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
etentamig
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07728188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07728188.